ROG: No rays of hope for TIGIT at ASCO2022

Roche recently announced the failure of co-primary progression free survival endpoints in both of its 1st line TIGIT trials in non-small (SKYSCRAPER -1) and small cell (SKYSCRAPER-02) lung cancer. ASCO 2022 saw the presentation of the full details from its small cell lung cancer trial.